



RPG LIFE SCIENCES LIMITED
Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

July 29, 2026

National Stock Exchange of India Limited

Plot No. C/1, "G" Block, Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Security Code: 532983

Dear Sirs /Madam,

Sub: Press Release

Please find enclosed herewith a copy of press release titled as "RPG Life Sciences Announces Strategic API Initiative to Accelerate Next Phase of Growth".

Kindly take the above on record.

Thanking you,

Yours Sincerely,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head- Legal & Company Secretary

End: as above

RPG Life Sciences Announces Strategic API Initiative to Accelerate Next Phase of Growth

API business to be transferred to wholly owned subsidiary RPG Active Pharma; India Life Sciences Fund managed by InvAscent to invest in RPG Active Pharma; RPG Active Pharma to acquire Actis Generics.

Key Highlights

- RPG Life Sciences executes agreement to transfer its API business on a slump sale basis to its wholly owned subsidiary, RPG Active Pharma Limited.
- RPG Active Pharma to raise an initial amount upto INR 243 crore from funds managed by InvAscent.
- RPG Active Pharma to acquire 100% equity share capital of Actis Generics Private Limited (Actis).

Mumbai, 29 July 2026: RPG Life Sciences Limited ("RPG Life Sciences" or "RPG LS") today announced the execution of a Business Transfer Agreement for the transfer of the Company's Active Pharmaceutical Ingredients (API) business to RPG Active Pharma Limited ("RPG Active Pharma" or "RPGAP"), a wholly owned subsidiary of RPG Life Sciences, as a going concern on a slump sale basis.

The proposed transfer is part of RPG Life Sciences' strategy to create a focused API business with dedicated capital, sharper management attention and greater strategic flexibility, while the Company also continues to build its formulations business. This business has been created at a time when the global pharmaceutical supply chains are undergoing structural realignment and India is increasingly emerging as a preferred destination for reliable, high-quality API manufacturing.

The Company has entered into an investment agreement to forge a strategic partnership with InvAscent, a healthcare-focused private equity investor, through an investment in RPG Active Pharma. The partnership brings together RPG Life Sciences' pharmaceutical experience, manufacturing capabilities and execution track record with InvAscent's 20-years' experience of investing in and scaling pharma businesses. Accordingly, funds managed by InvAscent will make an initial investment of an amount upto Rs. 243 cr. in RPG Active Pharma. The agreement envisages investments by the Company and InvAscent upto Rs. 700 cr. in RPGAP in tranches. The investment is expected to provide RPG Active Pharma with the capital and strategic support required to strengthen manufacturing infrastructure, expand the product portfolio, enhance process development capabilities and pursue organic and inorganic growth opportunities.

In addition, the RPG Active Pharma has also executed a Share Purchase Agreement for acquisition of 100% equity share capital of Actis Generics Private Limited - an API manufacturing company based in Visakhapatnam. The proposed acquisition is expected to expand RPG Active Pharma's manufacturing base, broaden its operating platform and support its strategic growth objectives.

The investment by India Life Sciences Fund - a life sciences focused fund – and the proposed acquisition of Actis Generics are intended to establish RPG Active Pharma as a focused API manufacturer for the next phase of RPG Life Sciences' API growth. RPG AP will focus on augmenting its manufacturing capabilities, expanding its API portfolio and serving customers across domestic and international markets with a strong emphasis on quality, reliability and long-term partnerships.

The transactions are subject to customary regulatory approvals and pre-closing conditions.

Commenting on the development, Ashok Nair, Managing Director, RPG Life Sciences, said:

"Building a meaningful and scalable presence in APIs has been a strategic priority for RPG Life Sciences. RPG Active Pharma gives us a focused business to pursue this opportunity with greater speed, discipline and scale. We are pleased to partner with InvAscent, whose pharma investing experience and long-term partnership approach complements our vision for the business. The proposed acquisition of Actis Generics further strengthens this business and supports our ambition to build a high-quality API business with expanded manufacturing capabilities, a broader product portfolio and the ability to create sustainable value for all stakeholders."



Commenting on the partnership, Dr. Jeevak Gupta, Managing Director, Invascent, said:

"We are excited to partner with RPG Life Sciences in building RPG Active Pharma into a differentiated API business. RPG Life Sciences has established pharmaceutical capabilities, a strong operating foundation and a clear ambition to scale its API business. We believe RPG AP is well positioned to benefit from the long-term growth opportunity in high-quality API manufacturing, and we look forward to supporting the business through capital, strategic guidance and our healthcare sector experience."

Khaitan & Co. acted as the legal counsel and structuring advisor to RPG group for the investment transaction. o3 Capital acted as an exclusive financial advisor, Quillon Partners acted as legal counsel and Deloitte undertook financial due diligence on the acquisition of Actis by RPG Active Pharma.

About RPG Life Sciences Limited

RPG Life Sciences Limited, part of RPG Group, is an integrated, research-based pharmaceutical company operating in domestic and international markets across branded formulations, global generics and synthetic APIs. The Company develops, manufactures and markets a wide range of quality and affordable medicines and remains focused on innovation, operational excellence and sustainable long-term growth.

About RPG Active Pharma Limited

RPG Active Pharma Limited is a subsidiary of RPG Life Sciences established to build a focused API business with capabilities across product development, manufacturing and commercialization. RPG Active Pharma will focus on strengthening manufacturing, expanding its product portfolio and pursuing strategic opportunities to build a diversified API platform serving domestic and international customers.

About RPG Group (www.rpggroup.com)

RPG Group, established in 1979, is one of India's fastest-growing business groups with a turnover of US\$ 5.2 billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

About Invascent

Established in 2005, InvAscent is India's leading life sciences-focused private equity firm with ~USD 850 million in capital raised to date and investments in 39 companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and health tech.

Contacts: RPG Life Sciences Media Contact: Sunaina Jairath Mobile: +91 9811645243 E-mail: sunaina@rpg.in	Contacts: Invascent Jeevak Gupta Mobile: +91 9741536677 E-mail: jeevak.gupta@invascent.com
--	--

